Signs Your Doctor May Be Lying To You
Signs Your Doctor May Be Lying To You
🚩 “Your BMI isn’t high enough.”
🚩 “You have to fail a diet first.”
🚩 “We don’t treat that unless you have diabetes.”
Some providers still think you have to suffer first to “deserve” help.
But your metabolic health matters now — not after you get worse.
I talk about real options, real science, and how to access safe, affordable GLP‑1s without gatekeeping.
💉 Compounded Sema: 12 doses from $249
💉 Compounded Tirz: 12 doses from $499
🧪 U.S. 503a/503b pharmacies | FSA/HSA eligible
📍Link in bio → Tap “Get Started” → Fill out the form
Your provider should empower you — not gaslight you.
Many patients seeking weight management and metabolic health care are often met with confusing or misleading information from healthcare providers, especially concerning the eligibility criteria for treatments such as GLP-1 receptor agonists. GLP-1s, including medications like semaglutide (Sema) and tirzepatide (Tirz), have become renowned for their effectiveness in managing weight and improving metabolic conditions. However, some doctors impose arbitrary restrictions, such as stating that a patient’s BMI must be above 30, or 27 with comorbid conditions like PCOS, before they qualify for treatment. These gatekeeping tactics can delay necessary care and potentially worsen patients’ health outcomes. It is important to understand that metabolic health should be addressed promptly, rather than waiting until symptoms worsen or additional diagnoses like diabetes develop. A BMI threshold alone does not capture the full picture of an individual's health risks. Comorbidities such as hypertension, insulin resistance, or polycystic ovary syndrome warrant earlier intervention. Patients have the right to seek providers who prioritize empowerment and transparent communication rather than gaslighting or minimizing their concerns. Recent advancements have enabled compounded formulations of GLP-1 medications to be available at more affordable prices through U.S. 503a and 503b pharmacies, often covered by FSA/HSA plans. This accessibility allows more patients to initiate treatment without extensive barriers. Understanding the full spectrum of options and asking for evidence-based guidance can help patients avoid common pitfalls when navigating weight loss and metabolic therapies. In addition, staying informed about the latest scientific studies and treatment eligibility criteria helps patients advocate effectively for their health. Communities such as #glp1, #glp1journey, and #glp1weightlossjourney share valuable peer insights on personal experiences with these medications. Ensuring your healthcare provider is aligned with your goals and supports your journey toward optimal metabolic health is essential for long-term success.
